Acute lung injury (ALI) arises from an excessive inflammatory response, usually progressing to acute respiratory distress syndrome (ARDS) if not promptly addressed. There is currently a limited array of effective treatments available for ALI. In this study, we developed disulfide bond-bridged prodrug self-assembled nanoparticles (referred to as DSSS NPs). These nanoparticles were consisted of Dexamethasone (Dex) and stearic acid (SA), and were designed to target and treat ALI. DSSS NPs demonstrated a substantial drug loading capacity with 37.75 % of Dex, which is much higher than conventional nanomedicines (usually < 10 %). Moreover, they exhibited the potential to specifically target injured lung tissue and inflammatory microenvironment-responsive release drugs. Consequently, DSSS NPs reduced significantly the levels of pro-inflammatory cytokines and tissue damage in mice with ALI induced by lipopolysaccharide (LPS). Overall, DSSS NPs offer a promising strategy for treatment of acute lung injury.
Keyphrases
- inflammatory response
- lps induced
- lipopolysaccharide induced
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- mechanical ventilation
- toll like receptor
- oxide nanoparticles
- low dose
- oxidative stress
- high dose
- stem cells
- cancer therapy
- drug induced
- anti inflammatory
- adverse drug
- high fat diet induced
- walled carbon nanotubes
- adipose tissue
- risk assessment
- immune response
- physical activity
- climate change
- skeletal muscle